Drug Profile

Tilrekimig - Pfizer

Alternative Names: anti-IL4/13/TSLP - Pfizer; PF-07275315

Latest Information Update: 18 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Anti-inflammatories; Antiasthmatics; Skin disorder therapies
Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists; Thymic stromal lymphopoietin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II/III Chronic obstructive pulmonary disease
Phase II Asthma; Atopic dermatitis

Most Recent Events

09 Mar 2026 Phase-II/III clinical trials in Chronic obstructive pulmonary disease (unspecified route)
09 Mar 2026 Efficacy and adverse events data from a phase II trial in Atopic dermatitis released by Pfizer
09 Mar 2026 Pfizer plans a phase III trial for Atopic dermatitis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com